BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19146924)

  • 1. Interactions between riluzole and ABCG2/BCRP transporter.
    Milane A; Vautier S; Chacun H; Meininger V; Bensimon G; Farinotti R; Fernandez C
    Neurosci Lett; 2009 Mar; 452(1):12-6. PubMed ID: 19146924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
    Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F
    Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-glycoprotein expression and function are increased in an animal model of amyotrophic lateral sclerosis.
    Milane A; Fernandez C; Dupuis L; Buyse M; Loeffler JP; Farinotti R; Meininger V; Bensimon G
    Neurosci Lett; 2010 Mar; 472(3):166-70. PubMed ID: 20138122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
    Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.
    Zhou L; Schmidt K; Nelson FR; Zelesky V; Troutman MD; Feng B
    Drug Metab Dispos; 2009 May; 37(5):946-55. PubMed ID: 19225039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2).
    Römermann K; Helmer R; Löscher W
    Neuropharmacology; 2015 Jun; 93():7-14. PubMed ID: 25645391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.
    Lee YJ; Kusuhara H; Jonker JW; Schinkel AH; Sugiyama Y
    J Pharmacol Exp Ther; 2005 Jan; 312(1):44-52. PubMed ID: 15448171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds.
    Enokizono J; Kusuhara H; Ose A; Schinkel AH; Sugiyama Y
    Drug Metab Dispos; 2008 Jun; 36(6):995-1002. PubMed ID: 18322075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
    de Vries NA; Zhao J; Kroon E; Buckle T; Beijnen JH; van Tellingen O
    Clin Cancer Res; 2007 Nov; 13(21):6440-9. PubMed ID: 17975156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.
    Sampson KE; Brinker A; Pratt J; Venkatraman N; Xiao Y; Blasberg J; Steiner T; Bourner M; Thompson DC
    Drug Metab Dispos; 2015 Feb; 43(2):199-207. PubMed ID: 25388687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain penetration of WEB 2086 (Apafant) and dantrolene in Mdr1a (P-glycoprotein) and Bcrp knockout rats.
    Fuchs H; Kishimoto W; Gansser D; Tanswell P; Ishiguro N
    Drug Metab Dispos; 2014 Oct; 42(10):1761-5. PubMed ID: 25053619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Verapamil and riluzole cocktail liposomes overcome pharmacoresistance by inhibiting P-glycoprotein in brain endothelial and astrocyte cells: A potent approach to treat amyotrophic lateral sclerosis.
    Yang T; Ferrill L; Gallant L; McGillicuddy S; Fernandes T; Schields N; Bai S
    Eur J Pharm Sci; 2018 Jul; 120():30-39. PubMed ID: 29704642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and Dietary Regulation of Glyburide Efflux by the Human Placental Breast Cancer Resistance Protein Transporter.
    Bircsak KM; Gupta V; Yuen PY; Gorczyca L; Weinberger BI; Vetrano AM; Aleksunes LM
    J Pharmacol Exp Ther; 2016 Apr; 357(1):103-13. PubMed ID: 26850786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of interactions between breast cancer resistance protein (bcrp/abcg2) and selected antiepileptic agents.
    Cerveny L; Pavek P; Malakova J; Staud F; Fendrich Z
    Epilepsia; 2006 Mar; 47(3):461-8. PubMed ID: 16529607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein- and bcrp- deficient knockout mice.
    Geyer J; Gavrilova O; Petzinger E
    J Vet Pharmacol Ther; 2009 Feb; 32(1):87-96. PubMed ID: 19161460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
    Graber-Maier A; Gutmann H; Drewe J
    Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier.
    Do TM; Noel-Hudson MS; Ribes S; Besengez C; Smirnova M; Cisternino S; Buyse M; Calon F; Chimini G; Chacun H; Scherrmann JM; Farinotti R; Bourasset F
    J Alzheimers Dis; 2012; 30(1):155-66. PubMed ID: 22391220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier.
    Zhao R; Raub TJ; Sawada GA; Kasper SC; Bacon JA; Bridges AS; Pollack GM
    Drug Metab Dispos; 2009 Jun; 37(6):1251-8. PubMed ID: 19273529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.